Measuring daily activity in patients with ALS and healthy controls
Official title: Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects
Run by Centre Hospitalier Universitaire de Liege · NCT04882904 · Data updated 2026-11-12
This study is testing how active people with ALS are compared to healthy individuals by using a special device to track their daily movements over a year.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Liege Academic / other |
| Locations | 1 site (Liège, Liège) |
| Status | Recruiting |
| Started | September 25, 2020 |
| Main results expected | September 2026 |
| Study ends | December 2026 |
| Registry record updated | December 5, 2025 |
| Trial ID | NCT04882904 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old with a clinically defined or probable diagnosis of ALS.
✕Probably not a fit
Patients with significant cognitive disorders or other pathologies affecting motor function may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to continuously measure the activity levels of patients diagnosed with amyotrophic lateral sclerosis (ALS) and compare them with healthy control subjects. Approximately 20 ALS patients will be enrolled voluntarily and assessed every three months over a year. Participants will undergo various clinical examinations and tests, including the 6-minute walk test and electromyography, and will wear a device called Actimyo daily for one month to monitor their activity levels. The study seeks to gather comprehensive data on the daily living activities of ALS patients to better understand the disease's impact.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the daily activity patterns of ALS patients, potentially leading to improved management strategies.
How similar studies have gone: While similar studies have explored activity measurement in ALS, this specific approach using continuous monitoring with Actimyo is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm. * Over 18 years old. * Signed informed consent * If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period. Exclusion Criteria: * Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection. * Any other previous or present pathology having an impact on motor function. * Recent surgery or trauma (less than 6 months) in the upper or lower limbs. * Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion. * Patients participating in an interventional clinical trial.
Where it's running
-
CHR Citadelle
Liège, Liège, Belgium Recruiting
Study contacts
- Principal investigator: Margaux Poleur, MD — CHR Citadelle-CHU liège
- Study coordinator: Laurie MEDARD
- Email: Laurie.Medard@citadelle.be
- Phone: 43218222
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Implanted Brain-Computer Interface to Help People with Severe Arm Impairment
We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.
-
Brain-computer interface chat tool for people with ALS
This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.
-
BIIB147 safety and how it behaves in adults with ALS
This study tests BIIB147 in adults with ALS to see if it is safe and how the body handles it, including early and long-term effects.
-
Aims to restore UNC13A function in people with ALS
This trial tests TRCN-1023 in adults with ALS to see if it’s safe, tolerated, and shows early signs of benefit.
-
LTX-002 in adults with ALS
A study will test whether the experimental drug LTX-002 is safe and tolerable in adults with ALS and see how the body handles the drug and how it affects ALS indicators.
-
Repeated ultrasound-assisted blood-brain barrier opening in ALS
This trial tests whether repeatedly opening the blood-brain barrier with ultrasound is safe and may help people with ALS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.